The deal gives Arrowhead access to technologies developed by Novartis, a license to Alnylam intellectual property, and a pipeline of three preclinical RNAi drug candidates.
The new company will be focused entirely on hepatitis B, although officials previously said that Tekmira's other non-HBV RNAi programs would continue to advance.
The company was founded in 1999 to provide high-throughput target discovery and validation services for academic and industry partners.
The approach is designed to overcomes many of the limitations of existing techniques such as the cost of developing and maintaining knockout mice.
The method involves expressing long dsRNA in plant chloroplasts to prevent them from being processed into less-effective siRNAs.
In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.
Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.
Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.
Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.